Spectral Medical's Stock Target Lowers to $0.35

Market by 2FIRSTS.ai
Oct.25.2023
Spectral Medical's Stock Target Lowers to $0.35
Spectral Medical's stock target lowered to $0.35 by Stifel Nicolaus, impacting the company's position in the tobacco industry.

According to BayStreet's report on October 24th, the stock price target of Spectral Medical, a manufacturer of smokeless products, has been downgraded from 0.40 CAD to 0.35 CAD by stock analyst Stifel Nicolaus in a research report.

 

According to reports, Standard Diversified Inc is a holding company that owns and operates subsidiary companies in various industries, including other tobacco products, insurance, and outdoor advertising. They engage in the production and marketing of both smokeless and smoking tobacco products, as well as next-generation tobacco products. Their divisions manufacture and market moist snuff, and also serve as contract manufacturers and marketers of chewing tobacco products.

 

Notice

1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.

2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.

3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.

Copyright

This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.

This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.